RxDoctor Payments Data

William Lensing, MD

Family Medicine · Plano, TXNPI 1982612990

Payments from drug & device makers

$9,465in general payments, 2019–2025

Across 538 payments — averaging $17.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$1K
  • AbbVie$907
  • GSK$813
  • Lilly USA, LLC$491
  • Amgen$473
  • plus $4K from 46 others

What the payments were for

  • Food & beverage$9,454100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,465 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$201,760
Medicare patients
580
Services billed
2,363

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin76$102,393
FarxigaDapagliflozin Propanediol73$94,212
OzempicSemaglutide60$84,933
EliquisApixaban44$54,149
JanuviaSitagliptin Phosphate31$51,226
MounjaroTirzepatide18$34,509
XareltoRivaroxaban16$21,859
TrulicityDulaglutide19$20,873
ViberziEluxadoline11$20,450
RybelsusSemaglutide16$16,078
KerendiaFinerenone12$11,870
Breo ElliptaFluticasone/Vilanterol16$8,512
Atorvastatin Calcium920$6,764
SynthroidLevothyroxine Sodium100$6,546
Levothyroxine Sodium664$6,276

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$349$102,39376 claims
Novo NordiskOzempic, Rybelsus$1,249$101,01076 claims
AstraZenecaFarxiga$1,422$94,21273 claims
Lilly USA, LLCMounjaro, Trulicity$491$55,38337 claims
PfizerEliquis$175$54,14944 claims
MerckJanuvia$306$51,22631 claims
AbbVieViberzi, Synthroid$907$26,995111 claims
Johnson & JohnsonXarelto$173$21,85916 claims
BayerKerendia$278$11,87012 claims
GSKBreo Ellipta$813$8,51216 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$66$6,276664 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →